

Artery Stenosis Drug Market Report 2025: For Strategy Officers and Market Intelligence Teams

The Business Research Company's Artery Stenosis Drug Market Report 2025: For Strategy Officers and Market Intelligence Teams

LONDON, GREATER LONDON, UNITED KINGDOM, June 16, 2025

/EINPresswire.com/ -- [The Business Research Company](#)'s Latest Report

Explores Market Driver, Trends, Regional Insights - Market Sizing & Forecasts Through 2034

The Business
Research Company

The Business Research Company

What Does The Data On The [Artery Stenosis Drug Market Size](#) Indicate?

The artery stenosis drug market size has grown strongly in recent years. It will grow from \$2.47

“

It will grow to \$3.34 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%.

”

*The Business Research
Company*

billion in 2024 to \$2.63 billion in 2025 at a compound annual growth rate CAGR of 6.4%. The growth in the historic period can be attributed to the rising incidence of cardiovascular diseases, the growing geriatric population, increasing awareness about arterial health, the growing use of telemedicine in patient monitoring, and the improved healthcare infrastructure.

What's On The Horizon For The Artery Stenosis Drug

Market?

The artery stenosis drug market size is expected to see strong growth in the next few years. It will grow to \$3.34 billion in 2029 at a compound annual growth rate CAGR of 6.2%. The growth in the forecast period can be attributed to the increasing obesity and diabetes prevalence, growing demand for minimally invasive treatments, the expansion of healthcare access in emerging markets, the rising healthcare expenditure, and the rising prevalence of diabetes and obesity. Major trends in the forecast period include personalized medicine approaches, increased adoption of combination therapies, advancements in diagnostic techniques, rising focus on preventative cardiology, and the development of novel drug delivery systems.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=24151&type=smp>

What Are The Key Growth Drivers Of The Artery Stenosis Drug Market?

The rising prevalence of diabetes and obesity is expected to propel the growth of the artery stenosis drug market going forward. Diabetes is a long-term condition where the body either produces insufficient insulin or is unable to use it properly, resulting in elevated blood sugar levels, whereas obesity is a health condition marked by an excess of body fat, raising the likelihood of numerous health issues. This rise in diabetes and obesity is growing due to a lack of regular physical activity associated with increasingly sedentary work environments and screen-based leisure activities, which contribute to weight gain and insulin resistance. Artery stenosis drugs are needed in diabetes and obesity, as both conditions promote plaque buildup in arteries, increasing the risk of heart attacks and strokes. For instance, in March 2024, according to the World Health Organization, a Switzerland-based agency of the United Nations, in 2022, 2.5 billion adults were overweight, with 890 million living with obesity. Therefore, the growing prevalence of diabetes and obesity is driving growth in the artery stenosis drug market.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/artery-stenosis-drug-global-market-report>

Who Are The Main Players In The Artery Stenosis Drug Market?

Major companies operating in the artery stenosis drug market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Novartis AG, Sanofi S.A., GSK plc, Takeda Pharmaceutical Company Limited, Medtronic plc, Gilead Sciences Inc., Amgen Inc., Baxter International Inc., Regeneron Pharmaceuticals Inc., Lupin Limited, Alnylam Pharmaceuticals.

What Are The Emerging Trends In The Artery Stenosis Drug Market?

Major companies operating in the artery stenosis drug market are focusing on advancing therapeutic solutions, such as bempedoic acid, to address unmet medical needs in the treatment of hypercholesterolemia. Bempedoic acid is a first-in-class drug designed to lower LDL cholesterol levels in patients who cannot tolerate statins or need additional lipid-lowering therapy. For instance, in May 2022, Zydus Lifesciences Ltd., an India-based pharmaceutical company, launched Bemdac, a novel oral therapy for hypercholesterolemia, a new class of drug, in India. Bemdac contains bempedoic acid, a first-in-class drug designed to lower LDL cholesterol levels in patients who are unable to tolerate statins or require additional lipid-lowering therapy. The launch aims to provide a new treatment option that improves cardiovascular outcomes by targeting cholesterol synthesis in the liver while minimizing muscle-related side effects often associated with statin use.

How Is The Artery Stenosis Drug Market Segmented?

The artery stenosis drug market covered in this report is segmented –

- 1 By Drug Type: Antiplatelet Agents, Anticoagulants, Statins, Beta Blockers
- 2 By Mechanism Of Action: Platelet Aggregation Inhibitors, Thrombin Inhibitors, HMG-CoA Reductase Inhibitors, Beta-Adrenergic Antagonists
- 3 By Route Of Administration: Oral, Injectable, Transdermal
- 4 By Patient Type: Adults, Geriatric, Pediatric

Subsegments:

- 1 By Antiplatelet Agents: Aspirin, Clopidogrel, Ticagrelor, Prasugrel, Dipyridamole
- 2 By Anticoagulants: Warfarin, Heparin, Low Molecular Weight Heparins, Direct Oral Anticoagulants DOACs
- 3 By Statins: Atorvastatin, Simvastatin, Rosuvastatin, Pravastatin, Lovastatin
- 4 By Beta Blockers: Metoprolol, Atenolol, Propranolol, Carvedilol, Bisoprolol

What Are The Regional Insights Of The Artery Stenosis Drug?

North America was the largest region in the artery stenosis drug market in 2024. The regions covered in the artery stenosis drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Coronary Artery Bypass Graft Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/coronary-artery-bypass-graft-global-market-report>

Peripheral Artery Disease Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/peripheral-artery-disease-global-market-report>

Coronary Artery Disease Global Market Report 2025

<https://www.thebusinessresearchcompany.com/report/coronary-artery-disease-global-market-report>

About The Business Research Company

Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/822588796>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.